Head to Head Contrast: Denali Therapeutics (NASDAQ:DNLI) Vs. JATT Acquisition (NYSE:JATT)
Head to Head Contrast: Denali Therapeutics (NASDAQ:DNLI) Vs. JATT Acquisition (NYSE:JATT)
Denali Therapeutics (NASDAQ:DNLI – Get Rating) and JATT Acquisition (NYSE:JATT – Get Rating) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.
Denali Therapeutics（纳斯达克股票代码：DNLI — 获取评级）和JATT收购（纽约证券交易所代码：JATT — 获取评级）都是医疗公司，但哪只是优势股？我们将根据两家企业的股息、估值、机构所有权、分析师建议、盈利能力、风险和收益进行比较。
Valuation and Earnings
估值和收益
This table compares Denali Therapeutics and JATT Acquisition's gross revenue, earnings per share (EPS) and valuation.
该表比较了Denali Therapeutics和JATT Acquition的总收入、每股收益（EPS）和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Denali Therapeutics | $48.66 million | 81.22 | -$290.58 million | ($2.47) | -11.78 |
| JATT Acquisition | N/A | N/A | $6.85 million | N/A | N/A |
| 总收入 | 价格/销售比率 | 净收入 | 每股收益 | 市盈率 | |
| 德纳利疗法 | 4,866 万美元 | 81.22 | -2.9058 亿美元 | (2.47 美元) | -11.78 |
| 收购 JATT | 不适用 | 不适用 | 685 万美元 | 不适用 | 不适用 |
JATT Acquisition has lower revenue, but higher earnings than Denali Therapeutics.
收购JATT的收入较低，但收益高于Denali Therapeutics。
Analyst Recommendations
分析师建议
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Denali Therapeutics | 0 | 0 | 8 | 0 | 3.00 |
| JATT Acquisition | 0 | 0 | 0 | 0 | N/A |
| 卖出评级 | 保持收视率 | 买入评级 | 强劲的买入评级 | 评分分数 | |
| 德纳利疗法 | 0 | 0 | 8 | 0 | 3.00 |
| 收购 JATT | 0 | 0 | 0 | 0 | 不适用 |
Denali Therapeutics currently has a consensus price target of $51.17, suggesting a potential upside of 75.83%. Given Denali Therapeutics' higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than JATT Acquisition.
Denali Therapeutics目前的共识目标价为51.17美元，这表明潜在的上涨空间为75.83％。鉴于Denali Therapeutics可能更高的上行空间，分析师显然认为Denali Therapeutics比收购JATT更有利。
Insider and Institutional Ownership
内部所有权和机构所有权
67.3% of Denali Therapeutics shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 12.7% of Denali Therapeutics shares are held by insiders. Comparatively, 20.0% of JATT Acquisition shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
67.3％的Denali Therapeutics股份由机构投资者持有。相比之下，48.0％的JATT收购股份由机构投资者持有。12.7％的Denali Therapeutics股份由内部人士持有。相比之下，20.0％的JATT收购股份由内部人士持有。强大的机构所有权表明，大型基金经理、对冲基金和捐赠基金认为，从长远来看，股票的表现将超过市场。
Profitability
盈利能力
This table compares Denali Therapeutics and JATT Acquisition's net margins, return on equity and return on assets.
该表比较了Denali Therapeutics和JATT Acquition的净利润率、股本回报率和资产回报率。
| Net Margins | Return on Equity | Return on Assets | |
| Denali Therapeutics | -273.34% | -33.85% | -23.08% |
| JATT Acquisition | N/A | -49.58% | 2.84% |
| 净利润 | 股本回报率 | 资产回报率 | |
| 德纳利疗法 | -273.34% | -33.85% | -23.08% |
| 收购 JATT | 不适用 | -49.58% | 2.84% |
Summary
摘要
Denali Therapeutics beats JATT Acquisition on 5 of the 9 factors compared between the two stocks.
与两只股票相比，Denali Therapeutics的9个因素中有5个超过了JATT的收购。
About Denali Therapeutics
关于德纳利疗法
(Get Rating)
（获取评分）
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
生物制药公司Denali Therapeutics Inc. 在美国发现并开发了神经退行性疾病的候选治疗药物。它提供富含亮氨酸的重复激酶2（LRRK2）抑制剂候选产品，包括BIIB122/DNL151，一种小分子抑制剂，目前处于治疗帕金森氏病的I期和Ib期临床试验中。该公司还开发了用于治疗亨特综合征的 DNL310，正在进行第 I/II 期临床试验；DNL343，正在进行肌萎缩性侧索硬化症 (ALS) 的 1 期临床试验；AR443820/DNL788 完成了治疗 ALS、多发性硬化症 (MS) 和阿尔茨海默氏病的 I 期临床试验；以及 SAR443122/DNL758，正在进行 II 期临床试验治疗皮肤红斑狼疮。它与武田制药公司、基因泰克公司、赛诺菲、F-star Gamma Limited、f-star Biotechnologsche Forschungs-Und Entwicklungsges M.BH、F-star Biotechnologs Limited、F-Star Biotechnologs-Und、F-Star BiotechnologsGes M.BH、F-Star Biotechnologs Limited、Genzyme Corporation、哈佛大学、迈克尔·福克斯基金会和CenKG. 在神经退行性疾病领域开发反义疗法。该公司前身为SPR Pharma Inc.，并于2015年3月更名为Denali Therapeutics Inc.Denali Therapeutics Inc. 成立于2013年，总部位于加利福尼亚州南旧金山。
About JATT Acquisition
关于收购 JATT
(Get Rating)
（获取评分）
JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.
JATT Acquisition Corp没有重大业务。它打算与一个或多个企业或实体进行合并、资本股份交换、资产收购、股份购买、重组或类似的业务合并。该公司打算将重点放在主要在生命科学领域运营的业务上。JATT Acquisition Corp成立于2021年，总部位于开曼群岛的大开曼岛。
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Denali Therapeutics 每日的新闻和评级 -在下面输入您的电子邮件地址，通过Marketbeat.com的免费每日电子邮件时事通讯接收Denali Therapeutics及相关公司的最新新闻和分析师评级的简明每日摘要。